Viral Vector and Plasmid Manufacturing Market Size, Share & Analysis by Application, Technology and Forecast 2030

The global viral vector and plasmid manufacturing market represents the market scenario of the viral vector and plasmid products and services across the world, taking into account key companies and their offerings in the market.

The advent of advanced therapies including gene therapy and cell therapy, which employ the use of vectors has created a huge buzz in the field of medicine in the past few decades. Therapies that require genetic modification, including the introduction of therapeutic DNA/gene into a patient's body or cell, demonstrated tremendous potential for the treatment of several critical diseases, including cancer, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis, among others.

The global viral vector and plasmid manufacturing market was estimated to reach $5.86 billion in 2030 , growing at a significant CAGR of 16.28% during the forecast period from 2020 to 2030.

Growth Factors

Rising prevalence of cancer, genetic disorders, and infectious diseases: Rising prevalence of cancer, genetic diseases, and infectious diseases is generating high demand for vector-based gene therapies, cell therapies, and vaccines, and therefore acting as one of the key driving factors for the growth of the global viral vector and plasmid manufacturing market. The most common types of cancers include breast cancer, lung cancer, prostate cancer, colon, and rectum cancer. Among these, lung cancer accounts for most of the cancer deaths, followed by breast cancer and colorectal cancer, according to the World Health Organization.
Rapid uptake of viral and plasmid vectors for the development of innovative therapies: Viral and non-viral vectors are increasingly being used for the development of novel therapies. These vectors are helpful in achieving in-vivo delivery of gene to a targeted cell or tissue. Viral vectors such as adeno-associated virus, lentivirus, and retrovirus are some of the commonly used vectors utilized in several clinical and preclinical trials evaluating gene and cell therapy products as well as vaccines.
Increasing number of clinical studies for the development of gene therapy: Currently, the global gene therapy market is witnessing an increasing number of clinical trials, offering a lucrative opportunity for the growth of viral vector and plasmid manufacturing market.
Favorable funding scenario for vector-based therapies: Preclinical and clinical trials, analyzing the effectiveness of any therapy, require adequate funding because of the high cost involved in manufacturing and development of the new therapy. Huge availability of grants and funds for conducting research and development activities related to vector-based cell and gene therapies is actively promoting the growth of the viral vector and plasmid manufacturing market.

Market Segmentation

Market Outlook by Vector Type

The vector type market segment is further categorized into plasmid DNA and viral vector. Both viral vector and plasmids have gained widespread success, owing to the promising results displayed by them in preclinical and clinical studies of cell and gene therapies as well as vector-based vaccine products.

Among these two classes of vectors, viral vectors account for majority of the market share that is mainly attributable to the availability of a large variety of viral vector options in the market and the effectiveness displayed by each of them in the treatment of various diseases. The market is largely dominated by viral vectors that contributed to maximum of the total market share in 2019.

By Disease Type

The disease type segment is further categorized into cancer, genetic disease, infectious disease, cardiovascular disease, and other diseases. The global viral vector and plasmid manufacturing market, by disease, is largely dominated by the cancer segment that contributed to maximum of the total market share in 2019. The cancer segment is expected to register a double digit CAGR during the forecast period between 2020 and 2030. This is mainly attributed to the progress made in vector-based CAR-T cell therapies and increasing investments in the field of oncology for the development of advanced therapies.

However, among the different disease types, the infectious disease segment is expected to account for the highest CAGR during the forecast period between 2020 and 2030, owing to the increasing investments in the infectious disease sector, globally, for the development of advanced therapies to protect against infectious disease pandemics and outbreaks.

By Region

North America dominated the global viral vector and plasmid manufacturing market in 2019. The presence of a large number of well-equipped vector manufacturing facilities with advanced infrastructure and the strong investments in the biomanufacturing sector are significantly promoting the growth of the viral vector and plasmid manufacturing market in North America.

The North America viral vector and plasmid manufacturing is largely dominated by the U.S., owing to the rapid adoption rate of vector-based gene and cell therapy products, which has led to an increased demand for viral vectors and plasmids.

However, among all the regions, Asia-Pacific is expected to witness the highest CAGR during the forecast period between 2020 and 2030. This is mainly attributed to the strong potential of emerging nations of Asia-Pacific including Japan, India, Australia, South Korea, and Singapore, among others.

Get Free Sample Report - https://bisresearch.com/requestsample?id=866type=download

Key Questions Answered

What is a vector and what is its importance in the medical industry? What are the major characteristics and types of vectors? What are the areas of application of vectors?
What are the major advancements in viral vector and plasmid manufacturing? What are the key trends of the global viral vector and plasmid manufacturing market? How is the market evolving and what is its future scope?
What are the major drivers, challenges, and opportunities of the global viral vector and plasmid manufacturing market?
What are the key developmental strategies implemented by the key players of the global viral vector and plasmid manufacturing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
What is the regulatory scenario of the global viral vector and plasmid manufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of viral vector and plasmid manufacturing products?
What are major milestones in patenting activity in the global viral vector and plasmid manufacturing market?
What was the market size of the global viral vector and plasmid manufacturing market in 2019 and what is the market size anticipated to be in 2030? What is the expected growth rate of the global viral vector and plasmid manufacturing market during the period between 2020 and 2030?
What is the global market size for manufacturing plasmids and different types of viral vectors available in the global viral vector and plasmid manufacturing market in 2019? What are the key trends of the market with respect to different vectors and which vector type is expected to dominate the market in 2030?
What are the different disease areas where plasmids and viral vectors are employed in the global viral vector and plasmid manufacturing market? Which disease type dominated the market in 2019 and is expected to dominate in 2030?
What are the different applications associated with viral vector and plasmid manufacturing? What was the contribution of each of the application areas in the global viral vector and plasmid manufacturing market in 2019 and what is it expected in 2030?
Which region is expected to contribute the highest sales in the global viral vector and plasmid manufacturing market during the period between 2019 and 2030? Which region and country carries the potential for the significant expansion of key companies for different viral vector and plasmid manufacturing? What are the leading countries of different regions that contribute significantly toward the growth of the viral vector and plasmid manufacturing market?
What are the key players of the global viral vector and plasmid manufacturing market and what is their role in the market? What is the market share of the key players in 2019?